Logotype for ICU Medical Inc

ICU Medical (ICUI) Q4 2012 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for ICU Medical Inc

Q4 2012 earnings summary

6 Nov, 2026

Executive summary

  • FY12 revenue rose 4.9% to a record $316.9M; growth in oncology, infusion therapy and TEGO offset the expected critical care decline.

  • Gross margin expanded 230 bps to 49.4%; net income was $41.3M, or $2.80 diluted EPS.

  • Debt-free year-end position included $226.2M in cash, cash equivalents and investment securities, with record operating cash flow of $66.3M.

Financial highlights

  • FY12 total revenue was $316.9M vs. $302.2M in FY11; net sales were $316.3M vs. $301.6M.

  • Operating income was $61.3M vs. $65.2M; net income was $41.3M vs. $44.7M.

  • Diluted EPS was $2.80 vs. $3.15; basic EPS was $2.90 vs. $3.23.

  • Gross profit increased to $156.5M from $142.4M; gross margin rose to 49.4% from 47.1%.

  • Operating cash flow reached $66.3M vs. $64.5M; cash and investments ended the year at $226.2M vs. $160.0M.

Outlook and guidance

  • FY13 U.S. Hospira sales were expected to be comparable to or slightly below FY12, with Q1 orders planned lower and normal levels expected in Q2–Q4.

  • FY13 outlook called for modest growth in other domestic, international and infusion therapy sales; significant oncology growth; and lower critical care sales.

  • FY13 SG&A and R&D were each expected at ~27% and ~3% of revenue, respectively; effective tax rate was expected at ~34%.

  • FY13 capital expenditures were estimated at $30M–$35M, mainly for Salt Lake City capacity expansion, manufacturing equipment and IT.

  • New product launches, expanded sales and marketing, R&D and possible acquisitions were identified as priorities for profitable growth.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from ICU Medical